Skip Over Navigation Links



Boston University Clinical and Translational Science Institute

Lisa Gagalis, R.N. and research participant Ashley Mendez

Lisa Gagalis, R.N. (right), a study coordinator at BU Medical Campus, performs lung function testing on research participant Ashley Mendez, who is enrolled in a clinical trial of omalizumab, an antibody-based treatment for asthma. (Vivian Borek Photo)

Boston, Massachusetts

Principal Investigator
David M. Center, M.D., Boston University


The Boston University Clinical and Translational Science Institute (BU CTSI) will integrate, connect and expand research and programs across traditional academic departments and schools. The institute will act as a bridge between disciplines to facilitate interactions by incorporating multiple key programs that support the university-wide commitment to a home for translational research.

The CTSA grant will allow the institute to build on existing strengths to create an environment linking faculty members, trainees and university programs to speed the translation of innovations in medical science to improve maintenance of health and diagnosis and treatment of diseases and share these innovations with other university-based CTSAs. The BU CTSI environment also will support the bidirectional development and translation of ideas that begin in the clinic to the BU scientific community and back to identify new ways to improve health and delivery of health care services. Moreover, the institute will significantly enhance existing partnerships with Boston's community health centers, transforming the conduct of clinical and translational research by infusing it with community-based perspectives and needs.

Harvard Catalyst: The Harvard Clinical and Translational Science Center

Akiko Yabuuchi, Ph.D.

Akiko Yabuuchi, Ph.D., of Children's Hospital Boston, conducts stem cell research inside a clean room. (Harvard University Photo/Justin Ide)

Boston, Massachusetts

Principal Investigator
Lee M. Nadler, M.D., Harvard University


Established in 2008, Harvard Catalyst is dedicated to improving human health by enabling collaboration and providing tools, training and technologies to clinical and translational investigators. As a shared enterprise of Harvard University, its 11 schools and 17 academic health care centers, Harvard Catalyst resources are available to all faculty, regardless of institutional affiliation or academic degree. To this end, the CTSA serves as a convener, connector and catalyst, providing integrated resources, education and funding to speed and improve the quality of clinical and translational research at Harvard.

Harvard Catalyst makes available an extensive portfolio of resources for researchers, including consultations for biostatistics, bioinformatics and regulatory support; education and training; pilot funding opportunities; clinical research services; informatics tools; and community-based population research. Research and programmatic initiatives also include child health, faculty diversity and health disparities. The organization’s innovative informatics tools — Profiles, the Shared Health Research Information Network (SHRINE) and eagle-i — have been adopted throughout the University and widely used outside Harvard to enable investigators to find collaborators, study participants and research resources. Since 2009, researchers also have benefited from the Harvard Catalyst institutional review board (IRB) cede review form, which allows investigators to request a single IRB review when conducting multisite studies.

Harvard Catalyst’s goal is to transform clinical and translational research at the University by creating a “One Harvard” community and culture committed to improving health.

Tufts Clinical and Translational Science Institute

Harry P. Selker, M.D., M.S.P.H., and James Roosevelt, Jr.

Harry P. Selker, M.D., M.S.P.H. (right), Dean of Tufts CTSI, and James Roosevelt, Jr., President and CEO of Tufts Health Plan, at the Tufts CTSI conference on the Affordable Care Act. (Tufts University Photo/Matthew Modoono)

Boston, Massachusetts

Principal Investigator
Harry P. Selker, M.D., M.S.P.H., Tufts University


Tufts Clinical and Translational Science Institute (CTSI) is based on the conviction that authentic involvement of the entire spectrum of clinical and translational research is critical to meeting the promise and the public’s needs for biomedical science. This involvement includes not only bench to bedside (“T1”) translation, but also translation into effective clinical practice (“T2”), care delivery and public health (“T3”), and health policy (“T4”).

Tufts CTSI’s 39 strategically chosen partners include 12 Tufts University schools and research centers, 10 Tufts affiliated hospitals, three additional academic institutions (Brandeis University, Northeastern University and RAND Corp.), nine community-based organizations (spanning health centers, public health organizations, physician networks and the Boston Museum of Science), and five industry partners (including three health plans). These partners share a joint mission: to promote research that will have an impact on health through translational research and cross-disciplinary collaborations. Together, they have outstanding and cooperative resources, opportunities and education across the T1–T4 spectrum.

University of Massachusetts Center for Clinical and Translational Science

Thomas Mayer, Craig Lilly and Joanne Meisner

Thomas Mayer, Ph.D., Craig Lilly, M.D., and Joanne Meisner stand in front of a robotic, liquid-handling instrument used to collect plasma, DNA and RNA from volunteer blood samples in the Biorepository Laboratory at the University of Massachusetts. (University of Massachusetts Medical School Photo)

Worcester, Massachusetts

Principal Investigator
Katherine Luzuriaga, M.D., University of Massachusetts Medical School, Worcester


The University of Massachusetts Center for Clinical and Translational Science, housed within the only public medical school in Massachusetts, has transformed the conduct of clinical and translational research by providing an academic home for all university bench-to-bedside-to-population investigators. By recruiting leaders and establishing innovative research core facilities, we aim to: 1) accelerate early phase translational studies and develop new therapies, devices and interventions based upon UMass discoveries; 2) integrate unique networks of clinical research and health care delivery in Central New England and Massachusetts to build and expand clinical effectiveness research and implementation research capacity and enhance patient and community outreach and participation in clinical/population-based research; 3) work collaboratively with all campuses and schools of the UMass system in developing programs, curricula and faculty support systems that promote careers in clinical and translational research.

The university has established the UMass Advanced Therapeutics Cluster (UMATC), which includes the RNA Therapeutics Institute, the Center for Stem Cell Biology and Regenerative Medicine, and the Gene Therapy Center. UMATC joins the Massachusetts Biologic Laboratories, Meyers Primary Care Institute and Commonwealth Medicine to speed discoveries in clinical and translational research.

Back to Funded Institutions